Omzo's all-in pricing model - one fee covering consultation, prescription, medication, and shipping - appears designed around the brand's published "no hidden fees" positioning
"These drugs have the potential to bring about substantial weight loss, particularly in the first year," says Juan Franco, co-lead researcher from Heinrich Heine University Dsseldorf, Germany
Same problem as FAERS and other reporting databases but way worse
This level of optimization is not necessary for most people
GLP-1 drugs are indicated for patients with BMI above 25 even without complications, or BMI above 23 with obesity-related conditions such as diabetes, hypertension, or fatty liver disease